Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Income towards Parent Company (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Income towards Parent Company for 9 consecutive years, with $85.4 million as the latest value for Q4 2025.

  • Quarterly Income towards Parent Company fell 35.12% to $85.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$334000.0 through Dec 2025, down 100.12% year-over-year, with the annual reading at -$362000.0 for FY2025, 100.13% down from the prior year.
  • Income towards Parent Company hit $85.4 million in Q4 2025 for Protagonist Therapeutics, up from -$39.3 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $207.4 million in Q1 2024 to a low of -$41.0 million in Q2 2022.
  • Historically, Income towards Parent Company has averaged $3.4 million across 5 years, with a median of -$31.0 million in 2021.
  • Biggest five-year swings in Income towards Parent Company: crashed 335.45% in 2021 and later soared 714.87% in 2024.
  • Year by year, Income towards Parent Company stood at $88.9 million in 2021, then crashed by 138.55% to -$34.3 million in 2022, then surged by 179.78% to $27.3 million in 2023, then soared by 381.7% to $131.7 million in 2024, then plummeted by 35.12% to $85.4 million in 2025.
  • Business Quant data shows Income towards Parent Company for PTGX at $85.4 million in Q4 2025, -$39.3 million in Q3 2025, and -$34.8 million in Q2 2025.